EAN 2020 | OPTIPARK trial: opicapone in clinical practice

Georg Ebersbach, MD, Movement Disorders Clinic, Beelitz‐Heilstätten, Germany, discusses the OPTIPARK trial (NCT02847442), a prospective, open-label, uncontrolled, single-group, multi-center trial in Parkinson’s disease patients with wearing-off motor fluctuations. In the study, patients with Parkinson’s disease and motor fluctuations were treated with opicapone for 3 or 6 months in addition to their current levodopa and other antiparkinsonian treatments. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).